Calcium alpha-ketoglutarate (Ca-AKG) ≥98% purity is a calcium salt of alpha‑ketoglutarate (AKG), a TCA‑cycle metabolite studied for aging biology and bone metabolism. It is a white to off‑white powder suitable for dietary supplement use.
| Benefit |
Typical study dose* |
Key human findings |
High-quality sources |
| Healthy aging biomarkers |
~1 g/day (SR) for 6–8 months |
Uncontrolled Rejuvant® user study reported ~8‑year reduction in DNA‑methylation age; exploratory and not placebo‑controlled. |
PMC |
| Frailty/healthspan (animal) |
Dietary Ca‑AKG in middle‑aged mice |
Extended lifespan, reduced frailty scores, ↓ inflammatory cytokines (e.g., IL‑6). |
Cell Metab |
| Bone metabolism |
6 g/day for 6 months (postmenopausal) |
Lowered bone resorption marker (CTX); BMD change small/non‑significant over 6 months. |
PubMed |
| Exercise/muscle |
Varies by salt (AKG blends) |
Human data mixed and often with other AKG salts (e.g., arginine‑AKG); translate cautiously. |
MDPI |
*Doses shown are typical in studies; products and formulations differ. Pending RCT (“ABLE”) is testing 1 g/day sustained‑release for 6 months.
Mechanistic highlights
- Energy/epigenetic co‑factor: AKG participates in the TCA cycle and acts as a co‑substrate for dioxygenases (TET/Jumonji), potentially shaping epigenetic programs linked to aging.
- Inflammation tone: Murine data show ↓ pro‑inflammatory cytokines (e.g., IL‑6), aligning with improved frailty scores.
- Bone biology: In aged models, AKG supports osteogenesis and limits bone loss via epigenetic effects.
Safety & practical use
- Usual supplemental range: 0.5–2 g/day; sustained‑release 1 g/day is under RCT evaluation.
- Tolerability: Small studies report good short‑term tolerability (e.g., 4.5 g/day in dialysis; 6 g/day in women) with metabolic benefits reported.
- Drug status: Dietary supplement, not an approved drug for disease treatment; human outcome benefits remain unproven pending RCTs.
- Medical oversight: Avoid in pregnancy/breastfeeding due to limited data; consult a clinician for kidney disease, calcium disorders, or interacting meds.
